Updated:
Spectral AI
Spectral AI, led by Wensheng Fan, is a Dallas-based public company developing DARPA-funded multispectral wound-imaging AI; FDA-cleared as of January 2026.
Spectral AI
Spectral AI was formed in 2023 as the surviving public entity after Rosecliff Acquisition Corp I, a SPAC, merged with the UK-based wound-imaging developer Spectral MD. The firm's core technology is the DeepView system, a handheld multispectral imaging device that uses proprietary algorithms to predict wound healing — specifically whether a burn requires surgical intervention. Originating from research funded by the Defense Advanced Research Projects Agency (DARPA) and other US government health agencies, DeepView was designed for battlefield triage but has since been positioned for civilian emergency rooms. As of early 2026, the company holds the US government's BARDA contract for burn diagnostics and is expanding into diabetic foot ulcers and pressure ulcers under its 2024 FDA Breakthrough Device designations. The firm's commercial posture is direct-to-hospital capital equipment sales, supplemented by recurring software-licensing and wound-cartridge revenue. Although Spectral AI is a single-entity corporation and not a diversified fund, it functions as a hardware-plus-AI diagnostics vehicle in a regulated medical-device pathway. The company's public filings show no separate venture arm or structured co-investment program. Its clinical validation work has involved major US burn centers, including University of Texas Southwestern and MedStar Washington Hospital Center. Geographically, the firm sources its US market entry from Texas but maintains R&D ties to its legacy UK operations. Headcount and revenue remain modest — the firm's SEC filings reflect fewer than 50 employees and pre-revenue commercial operations through late 2025. CEO Wensheng Fan, previously an executive at the pre-merger Spectral MD, continues to lead the public company. The board includes SPAC sponsor Peter Lacy and financial veterans tied to the original Rosecliff vehicle. January 2026: Spectral AI received FDA 510(k) clearance for its DeepView SnapShot M device, triggering the company's first US commercial launch (per the firm, January 2026). The structural differentiator for Spectral AI is its origin: government-funded battlefield medicine repurposed for civilian care under a public-company format. Unlike most medical-AI startups that remain venture-backed, Spectral AI's SPAC listing makes it directly accessible to public-markets investors, but exposes it to quarterly earnings pressure that typical pre-revenue AI firms avoid. Its pipeline is contract-gated — the BARDA contract remains the firm's primary revenue anchor — meaning commercial adoption outside government networks represents a secondary, unproven leg.
General information
Firm type
Asset Manager
Year founded
2023
AUM
Publicly traded; market cap ~$170M (Altss estimate)
Location
Region
North America
Country
United States
City
Dallas
Corporate office
Dallas, TX, United States
Principals
Wensheng Fan
CEO
Sector focus
Frequently asked questions
How does Spectral AI's DeepView technology differ from standard wound assessment?
DeepView uses multispectral imaging and proprietary machine-learning algorithms to analyze tissue composition non-invasively. Unlike visual assessment by clinicians — which misclassifies burn depth up to 30% of the time — the system provides a binary 'heal or non-heal' prediction within seconds. The technology originated from DARPA-funded research aimed at military burn triage, where rapid, accurate decisions are life-or-death.
Is Spectral AI a single-family office, a venture firm, or an operating company?
Spectral AI is a publicly traded medical-device company — not a family office or investment firm. It develops and sells its own diagnostics hardware and software. The entity formed in 2023 when Rosecliff Acquisition Corp I, a SPAC, merged with Spectral MD. It trades on NASDAQ under the ticker symbol MDAI.
Who runs investment and strategic decisions at Spectral AI?
As a single-entity operating company, Spectral AI does not have an investment committee in the allocator sense. Capital deployment decisions — primarily R&D and commercial scaling — are led by CEO Wensheng Fan and overseen by the board, which includes SPAC sponsor Peter Lacy. The firm has not disclosed any separate investment vehicle or family-office structure.
What government contracts anchor Spectral AI's revenue?
Spectral AI's most significant contract is with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services. The multi-year BARDA contract funds development and procurement of DeepView for burn wound triage. The firm also has historical funding relationships with DARPA and other US defense health agencies.
What does Spectral AI's SPAC origin mean for its balance sheet and governance?
Spectral AI went public through a de-SPAC merger, a route that typically prioritizes speed to market over traditional IPO scrutiny. Public filings show the company operates with modest cash reserves and pre-revenue status through late 2025, making it reliant on periodic capital raises — dilutive to existing shareholders — until commercial product sales materialize. Governance includes legacy SPAC directors alongside the operating team.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: